How should we deal with missing data in clinical trials involving alzheimer's disease patients?

Current Alzheimer Research

Volumn 8, Issue 4, 2011, Pages 421-433

  Coley, N ^a   Gardette, V ^a,b   Cantet, C ^a,b   Gillette Guyonnet, S ^a,b   Nourhashemi, F ^a,b   Vellas, B ^a,b   Andrieu, S ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer's disease; Clinical trial methodology; Data interpretation; Dropout; Missing data; Randomised controlled trials; Statistical methods

Indexed keywords

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING; ANALYTIC METHOD; ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITION; COMPLETE CASE ANALYSIS; CONTROLLED STUDY; DEATH; FEMALE; FUNCTIONAL STATUS; HUMAN; LAST OBSERVATION CARRIED FORWARD METHOD; LONGITUDINAL MIXED EFFECTS MODEL; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; MINI MENTAL STATE EXAMINATION; MULTIPLE IMPUTATION; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TREATMENT REFUSAL; TREATMENT WITHDRAWAL; VALIDITY; Z SCORE LAST OBSERVATION CARRIED FORWARD;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; LONGITUDINAL STUDIES; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT DROPOUTS; TIME FACTORS;

EID: 79959364066     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511795745339     Document Type: Article

References (48)

1. Altman DG. Missing outcomes in randomized trials: addressing the dilemma. Open Med 3(2): e51-3 (2009).
2. Gardette V, Coley N, Toulza O, Andrieu S. Attrition in geriatric research: how important is it and how should it be dealt with? J Nutr Health Aging 11(3): 265-271 (2007).
3. Mackinnon A. Statistical treatment of withdrawal in trials of anti- dementia drugs. Lancet 372(9647): 1382-1383 (2008); author reply 1383.
4. Deeg DJ, van Tilburg T, Smit JH, de Leeuw ED. Attrition in the Longitudinal Aging Study Amsterdam. The effect of differential inclusion in side studies. J Clin Epidemiol 55(4): 319-328 (2002).
5. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 7(5): 436-450 (2008).
6. Thomas RG, Berg JD, Sano M, Thal L. Analysis of longitudinal data in an Alzheimer's disease clinical trial. Stat Med 19(11-12): p. 1433-1440 (2000).
7. Coley N, Gardette V, Toulza O, Gillette-Guyonnet S, Cantet C, et al. Predictive factors of attrition in a cohort of Alzheimer disease patients. The REAL.FR study. Neuroepidemiology 31(2): p. 69-79 (2008).
8. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319(7211): p. 670-674 (1999).
9. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol (2010).
10. Baron G, Ravaud P, Samson A, Giraudeau B. Missing data in randomized controlled trials of rheumatoid arthritis with radiographic outcomes: a simulation study. Arthritis Rheum 59(1): p. 25-31 (2008).
11. Mazumdar S, Liu KS, Houck PR, Reynolds CF, 3rd. Intent-to-treat analysis for longitudinal clinical trials: coping with the challenge of missing values. J Psychiatr Res 33(2): p. 87-95 (1999).
12. Little R. Modeling the dropout mechanisms in longitudinal studies. J Am Stat Assoc 90: p. 1112-1121 (1995).
13. Little R, Rubin D. Statistical analysis with missing data. New York: Wiley (1987).
14. Fairclough DL, Thijs H, Huang IC, Finnern HW, Wu AW. Handling missing quality of life data in HIV clinical trials: what is practical? Qual Life Res 17(1): p. 61-73 (2008).
15. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biol Psychiatry 59(11): p. 1001-1005 (2006).
16. Molnar FJ, Hutton B, Fergusson D. Does analysis using last observation carried forward introduce bias in dementia research? CMAJ 179(8): p. 751-753 (2008).
17. Molnar FJ, Man-Son-Hing M, Hutton B, Fergusson DA. Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review. Open Med 3(2): p. e31-50 (2009).
18. Hendrix SB, Wilcock G. What we have learned from the Myriad trials. J Nutr Health Aging 13(4): p. 362-364 (2009).
19. Rubin D. Multiple imputation for nonresponse in surveys New York: John Wiley & Sons (1987).
20. Molenberghs G, Kenwood MG. Missing data in clinical studies Chichester: John Wiley & Sons Ltd (2007).
21. Graham JW. Missing data analysis: making it work in the real world. Annu Rev Psychol 60: 549-576 (2009).
22. Baraldi AN, Enders CK. An introduction to modern missing data analyses. J Sch Psychol 48(1): 5-37 (2010).
23. Nourhashemi F, Andrieu S, Gillette-Guyonnet S, Giraudeau B, Cantet C, Coley N, et al. Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study). BMJ 340: c2466.
24. Nourhashemi F, Gillette-Guyonnet S, Andrieu S, Rolland Y, Ousset PJ, Vellas B. A randomized trial of the impact of a specific care plan in 1120 Alzheimer's patients (PLASA Study) over a two-year period: design and baseline data. J Nutr Health Aging 12(4): 263-271 (2008).
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7): 939-944 (1984).
26. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189-198 (1975).
27. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 Suppl 2: S33-S39 (1997).
28. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74(12): 956-964 (2010).
29. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. Jama 302(23): 2557-2564 (2009).
30. Wood AM, White IR, Hillsdon M, Carpenter J. Comparison of imputation and modelling methods in the analysis of a physical activity trial with missing outcomes. Int J Epidemiol 34(1): 89-99 (2005).
31. Beunckens C, Molenberghs G, Kenward MG. Direct likelihood analysis versus simple forms of imputation for missing data in randomized clinical trials. Clin Trials 2(5): 379-386 (2005).
32. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 50(9): 739-750 (1993).
33. Lavori PW, Dawson R, Shera D. A multiple imputation strategy for clinical trials with truncation of patient data. Stat Med 14(17): 1913-1925 (1995).
34. Molenberghs G, Thijs H, Jansen I, Beunckens C, Kenward MG, Mallinckrodt C, et al. Analyzing incomplete longitudinal clinical trial data. Biostatistics 5(3): 445-464 (2004).
35. Siddiqui O, Ali MW. A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts. J Biopharm Stat 8(4): 545-563 (1998).
36. Prakash A, Risser RC, Mallinckrodt CH. The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. Int J Clin Pract 62(8): 1147-1158 (2008).
37. Houck PR, Mazumdar S, Koru-Sengul T, Tang G, Mulsant BH, Pollock BG, et al. Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methods. Psychiatry Res 129(2): 209-215 (2004).
38. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 7(2): 93-106 (2008).
39. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 11(1-2): 9-21 (2001).
40. Liu G, Gould AL. Comparison of alternative strategies for analysis of longitudinal trials with dropouts. J Biopharm Stat 12(2): 207-226 (2002).
41. Schafer J. Analysis of incomplete multivariate data. New York: Chapman & Hall (1997).
42. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 18(6): 681-694 (1999).
43. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338: b2393 (2009).
44. Harel O, Zhou XH. Multiple imputation: review of theory, implementation and software. Stat Med 26(16): 3057-3077 (2007).
45. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods 7(2): 147-177 (2002).
46. Dufouil C, Brayne C, Clayton D. Analysis of longitudinal studies with death and drop-out: a case study. Stat Med 23(14): 2215-2226 (2004).
47. Liu M, Wei L, Zhang J. Review of guidelines and literature for handling missing data in longitudinal clinical trials with a case study. Pharm Stat 5(1): 7-18 (2006).
48. Koss E, Peterson B, Fillenbaum GG. Determinants of attrition in a natural history study of Alzheimer disease. Alzheimer Dis Assoc Disord 13(4): 209-215 (1999).